Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fortress Biotech (FBIO) Consolidated Net Income (2016 - 2025)

Fortress Biotech has reported Consolidated Net Income over the past 13 years, most recently at -$5.5 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 79.03% year-over-year to -$5.5 million; the TTM value through Dec 2025 reached -$54.4 million, up 53.13%, while the annual FY2025 figure was -$33.0 million, 72.66% up from the prior year.
  • Consolidated Net Income for Q4 2025 was -$5.5 million at Fortress Biotech, down from $8.8 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $8.8 million in Q3 2025 and troughed at -$62.3 million in Q4 2021.
  • A 5-year average of -$35.5 million and a median of -$35.8 million in 2024 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: tumbled 159.57% in 2021 and later surged 133.07% in 2025.
  • Year by year, Consolidated Net Income stood at -$62.3 million in 2021, then increased by 7.92% to -$57.4 million in 2022, then skyrocketed by 49.89% to -$28.8 million in 2023, then rose by 8.54% to -$26.3 million in 2024, then surged by 79.03% to -$5.5 million in 2025.
  • Business Quant data shows Consolidated Net Income for FBIO at -$5.5 million in Q4 2025, $8.8 million in Q3 2025, and -$35.9 million in Q2 2025.